

Luxembourg-Bertrange: Various medicinal products

OJ S 60/2023 24/03/2023

Contract notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1. Name and addresses

Official name: Fédération des hôpitaux luxembourgeois (FHL), association sans but lucratif

Postal address: 5 rue des Mérovingiens

Town: Bertrange

NUTS code: LU Luxembourg

Postal code: 8070

Country: Luxembourg

Contact person: Cellule marchés, à l'attention de Madame Carla MOREIRA

E-mail: carla.moreira@fhlux.lu

Telephone: +352 42414211

Internet address(es):Main address: <https://www.fhlux.lu>**I.2. Information about joint procurement**

The contract is awarded by a central purchasing body

I.3. CommunicationThe procurement documents are available for unrestricted and full direct access, free of charge, at: <https://pmp.b2g.etat.lu/?page=entreprise>.[EntrepriseDetailsConsultation&id=527090&orgAcronyme=t5y](https://pmp.b2g.etat.lu/?page=entreprise.EntrepriseDetailsConsultation&id=527090&orgAcronyme=t5y)

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: <https://pmp.b2g.etat.lu/?page=entreprise.EntrepriseDetailsConsultation&id=527090&orgAcronyme=t5y>Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at: <https://pmp.b2g.etat.lu/?page=entreprise>.[EntrepriseDetailsConsultation&id=527090&orgAcronyme=t5y](https://pmp.b2g.etat.lu/?page=entreprise.EntrepriseDetailsConsultation&id=527090&orgAcronyme=t5y)**I.4. Type of the contracting authority**

Body governed by public law

I.5. Main activity

Health

Section II: Object

II.1. Scope of the procurement**II.1.1. Title**

Fourniture de médicaments divers (sous-groupes ATC L01 et L04), formes injectables intraveineuses, à 4 établissements membres de la Fédération des Hôpitaux Luxembourgeois (AGANTI23).

Reference number: Référence interne de la FHL: AGANTI23. Référence du PMP: 2300570.

II.1.2. Main CPV code

33690000 Various medicinal products

II.1.3. Type of contract

Supplies

II.1.4. Short description

L'objet du marché consiste dans la fourniture de médicaments divers (sous-groupes ATC L01 et L04), formes injectables intraveineuses. La description des fournitures demandées figure dans les documents de marché. Les établissements qui seront parties aux contrats à conclure à l'issue de la procédure sont : - le Centre Hospitalier Émile Mayrisch (CHEM), - le Centre Hospitalier de Luxembourg (CHL), - le Centre Hospitalier du Nord (CHdN), et - les Hôpitaux Robert Schuman (HRS).

II.1.5. Estimated total value

II.1.6. Information about lots

This contract is divided into lots: yes

Tenders may be submitted for all lots

Maximum number of lots that may be awarded to one tenderer: 7

II.2. Description

II.2.1. Title

Brentuximab vedotin

Lot No: 1

II.2.2. Additional CPV code(s)

33690000 Various medicinal products

II.2.3. Place of performance

NUTS code: LU Luxembourg

II.2.4. Description of the procurement

Brentuximab vedotin, forme injectable intraveineuse, 50 mg.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/06/2023 End: 31/05/2025

This contract is subject to renewal: yes

Description of renewals:

Les contrats seront reconductibles pour une durée supplémentaire d'un an.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Carfilzomib
Lot No: 2

II.2.2. Additional CPV code(s)

33690000 Various medicinal products

II.2.3. Place of performance

NUTS code: LU Luxembourg

II.2.4. Description of the procurement

Carfilzomib, forme injectable intraveineuse, 60 mg.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/06/2023 End: 31/05/2025

This contract is subject to renewal: yes

Description of renewals:

Les contrats seront reconductibles pour une durée supplémentaire d'un an.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Elotuzumab
Lot No: 3

II.2.2. Additional CPV code(s)

33690000 Various medicinal products

II.2.3. Place of performance

NUTS code: LU Luxembourg

II.2.4. Description of the procurement

Elotuzumab, formes injectables intraveineuses, 300 mg et 400 mg.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value**II.2.7. Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/06/2023 End: 31/05/2025

This contract is subject to renewal: yes

Description of renewals:

Les contrats seront reconductibles pour une durée supplémentaire d'un an.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information**II.2. Description****II.2.1. Title**

Natalizumab

Lot No: 4

II.2.2. Additional CPV code(s)

33690000 Various medicinal products

II.2.3. Place of performance

NUTS code: LU Luxembourg

II.2.4. Description of the procurement

Natalizumab, forme injectable intraveineuse, 20 mg/ml.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value**II.2.7. Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/06/2023 End: 31/05/2025

This contract is subject to renewal: yes

Description of renewals:

Les contrats seront reconductibles pour une durée supplémentaire d'un an.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Obinutuzumab

Lot No: 5

II.2.2. Additional CPV code(s)

33690000 Various medicinal products

II.2.3. Place of performance

NUTS code: LU Luxembourg

II.2.4. Description of the procurement

Obinutuzumab, forme injectable intraveineuse, 1000 mg, 1000 mg / 40ml.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/06/2023 End: 31/05/2025

This contract is subject to renewal: yes

Description of renewals:

Les contrats seront reconductibles pour une durée supplémentaire d'un an.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Pertuzumab

Lot No: 6

II.2.2. Additional CPV code(s)

33690000 Various medicinal products

II.2.3. Place of performance

NUTS code: LU Luxembourg

II.2.4. Description of the procurement

Pertuzumab, forme injectable intraveineuse, 420 mg, 420 mg /14 ml.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value**II.2.7. Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/06/2023 End: 31/05/2025

This contract is subject to renewal: yes

Description of renewals:

Les contrats seront reconductibles pour une durée supplémentaire d'un an.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information**II.2. Description****II.2.1. Title**

Vedolizumab

Lot No: 7

II.2.2. Additional CPV code(s)

33690000 Various medicinal products

II.2.3. Place of performance

NUTS code: LU Luxembourg

II.2.4. Description of the procurement

Vedolizumab, forme injectable intraveineuse, 300 mg, 20 ml.

II.2.5. Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6. Estimated value**II.2.7. Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/06/2023 End: 31/05/2025

This contract is subject to renewal: yes

Description of renewals:

Les contrats seront reconductibles pour une durée supplémentaire d'un an.

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Section III: Legal, economic, financial and technical information

III.1. Conditions for participation

III.1.1. Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

Voir les documents de marché.

III.1.3. Technical and professional ability

Selection criteria as stated in the procurement documents

Section IV: Procedure

IV.1. Description

IV.1.1. Type of procedure

Open procedure

IV.1.3. Information about a framework agreement or a dynamic purchasing system

IV.1.8. Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2. Administrative information

IV.2.2. Time limit for receipt of tenders or requests to participate

Date: 27/04/2023 Local time: 11:00

IV.2.3. Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4. Languages in which tenders or requests to participate may be submitted

French, German

IV.2.7. Conditions for opening of tenders

Date: 27/04/2023 Local time: 11:00

Section VI: Complementary information

VI.1. Information about recurrence

This is a recurrent procurement: yes

Estimated timing for further notices to be published:

Le calendrier prévisionnel de publication des prochains avis n'est pas connu.

VI.3. Additional information

Les Quantités prévisionnelles de commande (QP) sont confidentielles. La version du bordereau de prix téléchargeable sur le site internet du portail des marchés publics ne porte pas la mention des QP. Une version comportant la mention des QP doit être demandée à la FHL.

VI.4. Procedures for review**VI.4.1. Review body**

Official name: Sur base de l'article 3 de la loi du 10.11.2010: Monsieur le président du tribunal administratif

Postal address: 1 rue du Fort Thüngen

Town: Luxembourg

Postal code: 1499

Country: Luxembourg

Telephone: +352 421051

VI.5. Date of dispatch of this notice

21/03/2023